April 14, 2003 — Nanogen Inc. has launched three new products for detecting genetic mutations related to diseases, according to a news release.
The products are analyte specific reagents that can be used on Nanogen’s NanoChip microarray platform by laboratories to create and validate tests for identifying mutations linked to Alzheimer’s and Canavan disease, and beta thalassemia. Canavan is a genetic disorder primarily affecting infants of European Jewish descent; beta thalassemia is a disorder related to anemia.
The Alzheimer’s and Canavan reagents will be made available to research and clinical laboratories in the United States. A research-use only product for beta thalassemia has been launched in Europe, where there are likely more people with the mutation, the release said.